久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Novartis to team up with Chinese tech giants

By Liu Zhihua | China Daily | Updated: 2019-04-02 10:49
Share
Share - WeChat
Employees analyze data at a high-tech command center on the Novartis AG campus in Basel, Switzerland. [Photo/Agencies]

Swiss pharmaceutical giant Novartis AG is looking to further tap into China's healthcare market by bringing more innovative drugs, while enhancing collaborations with local biotech and technology companies to further digital transformation of healthcare, a top company official said.

Vas Narasimhan, CEO of Novartis, said he expects China to "become one of the top three markets for Novartis by sales in the coming years". The company is ready to bring more than 10 innovative medicines to China over the coming years, thanks to the country's commitment to further reform and opening-up, and its ongoing efforts to speed up new drug approvals, he said.

"Over the last 20 years China has been able to evolve from a country that was primarily focused on generic medicines and vaccines to now being able to bring the latest innovations," he said.

"China's strategy of opening-up to our industry and opening-up to innovation will benefit Chinese patients and also enable companies like us to keep investing in China."

In recent years, especially from five years ago, Chinese regulators have been streamlining and accelerating new drug approvals, with efforts such as increasing the head count of staff for new drug reviews and speeding up approvals for drugs in urgent clinical need or for treating rare diseases.

At the recently closed China Development Forum 2019, Wang Ping, director general of the department of drug registration under the National Medical Products Administration, revealed that China approved 48 new medicines in 2018, and reduced the approval period by a year.

"Now China's regulatory timelines are at the same level of what we see in the United States or in Europe," Narasimhan said, adding that Novartis got nine new medicines approved in China in the past two years alone, at a pace faster than ever.

Novartis, which spends more than $9 billion on research and development every year, runs an innovation hub in Shanghai, with an investment of $1 billion. The campus, with more than 700 scientists focusing mainly on research of cancer and liver diseases prevalent in Asia and China, is now playing an increasingly important role in new drug development.

"I think our investment in innovation is bringing a number of new launches to China in our portfolio over the next three years," Narasimhan said.

China is now the world's second-largest market for pharmaceuticals, second only to the United States. Iqvia, a healthcare information company, earlier said China's pharmaceutical market will reach $145 billion to $175 billion by 2022, compared with $122.6 billion in 2017.

The CEO said Novartis is also engaging with Chinese regulators and local partners to bring cell and gene therapies to China, which have been heralded as a breakthrough in treating many intractable illnesses.

Last September, Novartis announced a deal with Shanghai-based biotech company Cellular Biomedicine Group, for manufacturing Kymriah, a CAR-T cell therapy, or chimeric antigen receptor cell therapy, treatment for cancer. Kymriah has already been approved in Europe, Canada, and Australia and Novartis is looking to bring the same to China soon.

"I believe our collaboration with Chinese partners can help China become the leader among the emerging markets in bringing cell and gene therapies to countries," said Narasimhan, who presented a policy paper at the CDF 2019 with a wide range of recommendations to the Chinese government, including the regulatory framework, requirements for the research and applications, as well as the establishment of flexible payment mechanisms and alternative funding models.

Narasimhan said that digital technologies have been a major driver fueling the company's business expansion in China.

In addition to 40 biotech companies that Novartis currently has partnerships with, the company is also planning partnerships with technology companies in China.

On March 22, the company signed a global strategic partnership deal with Chinese tech giant Tencent to apply integrated big data, artificial intelligence and social media technologies for better patient outcomes on chronic diseases.

The CEO took the helm at Novartis last year and has envisioned a focused medicines company that's powered by data sciences and digital technologies and has launched a number of initiatives to transform Novartis while reshaping the healthcare sector using digital technologies.

"We began the partnership with Tencent in cardiovascular diseases to help identify patients who need care and help patients stay on the right medicine," said Narasimhan.

"Now we are expanding the collaboration to cover all the chronic diseases. This is one of our most advanced partnerships in the world and a model for the rest. Our strategy in China is about growth, innovation, and digital technologies."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产亚洲精| 国产九九免费视频网站 | 初爱视频教程在线观看高清 | 久久综合精品不卡一区二区 | 久久久国产精品免费视频 | 国产成人精品免费视频大全五级 | 国产一区二区三区在线观看免费 | 精品国产成人在线 | 18年大片免费在线观看 | 午夜男人女人爽爽爽视频 | 欧美视频精品在线 | 亚洲成人福利在线 | 日本天堂视频在线观看 | 欧美jizzhd欧美精品 | 久久国产欧美日韩精品免费 | 中文字幕一区二区三区亚洲精品 | 久久91精品国产一区二区 | 国产精品1区 2区 3区 | 成年人免费视频观看 | 国产精品揄拍一区二区久久 | 免费精品久久久久久中文字幕 | 国产深夜福利视频网站在线观看 | 久久不见久久见免费影院www日本 | 男女交性拍拍拍高清视频 | 午夜啪啪福利视频 | 黄.www | 黄色成人在线网站 | 日本黄页网站在线观看 | 精品在线一区 | 久久99精品一级毛片 | 亚洲欧美久久 | 国产精品久久做爰 | 国产精品一区在线播放 | 成人精品国产亚洲 | 成在线人免费视频 | 一区二区三区欧美在线 | a级国产乱理伦片在线观看99 | 久久久久久久久久久福利观看 | 日本无卡码一区二区三区 | 国产亚洲一区二区在线观看 | 欧美高清一区二区三区欧美 |